Back to Search
Start Over
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
- Source :
- Journal of Thoracic Oncology; May 2019, Vol. 14 Issue: 5 p793-801, 9p
- Publication Year :
- 2019
-
Abstract
- In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.
Details
- Language :
- English
- ISSN :
- 15560864 and 15561380
- Volume :
- 14
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Journal of Thoracic Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs48783218
- Full Text :
- https://doi.org/10.1016/j.jtho.2019.01.016